Celgene sells psoriasis pill to Amgen for $13.4 billion, clearing way for close of Bristol merger

(By Adam Feuerstein for STAT)

Amgen said Monday that it will buy the psoriasis pill Otezla from Celgene (CELGZ), which is selling the medicine to remove an antitrust obstacle from its planned merger with Bristol-Myers Squibb.  Continue reading article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.